Jakie są godziny otwarcia?

Poniedziałek 08:00 - 16:00 Wtorek 08:00 - 16:00 Środa 08:00 - 16:00 Czwartek 08:00 - 16:00 Piątek 08:00 - 16:00

Vaxican

First pre-clinical lead candidates are addressing HER2 and GD2 cancers, incl.

VAXiCAN is a science-driven biotechnology company based on:

🔬 VAXiCAN Therapeutics – a division focused on developing novel eVLP cancer vaccines

🧬 VAXiCAN Genomics – Oxford Nanopore Technologies Official Provider: next-generation sequencing services VAXiCAN is a pre-clinical stage biotechnology company with vision to create Next Generation Immunotherapeutics, develops unique novel platform of th

erapeutic cancer vaccines based on proprietary enveloped virus-like particles (Enveloped VLPs), which provide the safest and most effective way of instructing and strengthening the Patient's anticancer defence mechanisms. VAXiCAN eVLP platform is widely supported by fully owned and in-house developed novel dedicated proprietary elements of machine learning (ML) and artificial intelligence (AI). The path chosen by the VAXiCAN is the use of naturally occurring or genetically modified oncolytic viruses using an innovative antigen delivery method using insect models (most similar solutions use mammalian, fungal or completely synthetic models). VAXiCAN eVLP vaccines are designed to present the extracellular domains of cancer antigens while leveraging the immune system's mechanism to mimic viral infection, thereby enhancing antigen presentation through the recognition of pathogen-associated molecular patterns (PAMPs). This strategy not only stimulates a strong adaptive immune response characterized by the production of high-affinity antibodies and cytotoxic T cells crucial for targeting tumor cells, but also actively engages natural killer cells supported by memory cells. breast cancer, neuroblastoma, melanoma as well as HPV/HBV-related cancers with potential of at least two first-in-class drug candidates and at least one in the orphan drug and fast track regulatory designations. VAXiCAN also operates in the field of modern whole viral and protein sequencing acting as Oxford Nanopore certified partner. We specialize in bioinformatic analysis of full genomes of microorganisms, including bacteria, bacteriophages, human and animal viruses as well as full human genomes.

26/06/2026

🌎 BIO International Convention 2026
Four intense days. Dozens of meaningful conversations. One clear signal: the global biotech community is paying close attention to next-generation cancer immunotherapy and to what's coming out of Poland.

We were proud to be part of the Polish Pavilion alongside 30+ Polish biotech companies and institutions, organized by Polish Investment and Trade Agency (PAIH). The interest in our eVLP cancer vaccine platform, tiny engineered particles that teach the immune system to recognize and fight tumors, was exactly the validation we needed heading into a pivotal second half of 2026.

The conversations we've started in San Diego don't end here. They're the foundation for partnerships we're building toward clinical readiness.

Thank you to everyone who stopped by. And thank you to PAIH for bringing to the world's biggest stage.

🔬 The work continues.

17/06/2026

🌐 VAXiCAN is attending BIO International Convention 2026 in San Diego.
Cancer doesn't wait. And neither do we.
Find us here 👉 Exhibit Hall — Booth 1411 — Poland Pavilion

Our CEO Łukasz Rąbalski and CGO Mateusz Sagan are joining thousands of biotech leaders, investors, and innovators at , carrying with them a simple but powerful idea that started a few years ago in a lab in Gdańsk:
What if we could teach the immune system to fight cancer? Precisely. Safely. Efficiently.
That idea is now becoming a platform.

Our technology uses tiny engineered particles, designed to look like a virus, but harmless, to train the body's own immune system to recognize and destroy cancer cells. No guesswork. Targeted. Smart. Built on AI-driven science and next-generation sequencing.

📩 Attending ? Let's meet, reach out directly or contact us at [email protected]

🔗 https://bio2026.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=01015334

21/05/2026

The Person Who Makes It Happen ✅
Krzysztof Łepek, PhD
and Board Member at Sp. z o.o.

Every successful biotech company has one: the person who ensures brilliant science doesn't get lost in messy operations. That person is Krzysztof.

Co-founder and shareholder of Vaxican. Krzysztof’s toolkit is formidable: gene cloning, vector design across multiple expression systems, DNA/RNA isolation, PCR-based diagnostics and genetic engineering, recombinant protein production and purification, immune response testing, and extensive work with insect and mammalian cell cultures including recombinant proteins, viral vectors, and virus propagation.

What truly sets him apart is his ability to translate that scientific depth into operational methodology. He has built and developed advanced R&D laboratories — including BSL-3, GMP, and ISO 17025-compliant facilities, and designed the procedures for equipment maintenance, reagent handling, and safety that underpin everything Vaxican does.

What defines Krzysztof?
- R&D complex timelines, stakeholder alignment, regulatory requirements: he orchestrates it all while keeping teams focused and motivated.
- . In biotechnology there's no room for "close enough." Krzysztof maintains the uncompromising standards.
- As Vaxican grows, he anticipates bottlenecks and builds systems fit for the future.

13/05/2026

🇪🇺
realizuje projekt „Innowacyjne metody diagnostyczne i terapeutyczne wobec zwiększonego zagrożenia arbowirusami spowodowanego zmianami klimatycznymi” w ramach Programu Fundusze Europejskie dla Pomorza 2021-2027, Priorytetu FEPM.01 Fundusze europejskie dla konkurencyjnego i inteligentnego Pomorza, Działania FEPM.01.01 Badania i innowacje w przedsiębiorstwach, współfinansowanego z Europejskiego Funduszu Rozwoju Regionalnego

Opis projektu:
Opracowane zostaną protokoły izolacji RNA arbowirusów z próbek klinicznych i środowiskowych oraz startery do amplifikacji ich genomów, zoptymalizowany protokół przygotowania bibliotek NGS dostosowany do szybkiej diagnostyki. Synteza i funkcjonalność nanocząstek złota, umożliwiających penetrację błon komórkowych oraz skuteczne wiązanie i inaktywację cząsteczek wirusowych. Badania skuteczności, stabilności, biodostępności oraz bezpieczeństwa (toksyczność).
Stworzenie prototypu kompleksowego systemu diagnostycznego, jego wstępna walidacja na próbkach rzeczywistych oraz analiza porównawcza z metodami referencyjnymi.

Grupa docelowa odbiorców projektu:
- Laboratoria diagnostyczne
- Instytucje sanitarno-epidemiologiczne
- Ośrodki badawcze i uczelnie
- Firmy biotechnologiczne i farmaceutyczne
- Podmioty administracji zdrowia

Cel projektu
Celem projektu jest opracowanie zintegrowanej platformy diagnostycznej, obejmującej szybkie testy molekularne oparte na sekwencjonowaniu nanoporowym (ONT) oraz rozwój nowatorskich nanocząstek złota o potencjale przeciwwirusowym. Technologie te będą wspierać zarówno precyzyjne wykrywanie arbowirusów, jak i skuteczne ich unieszkodliwianie, co ma kluczowe znaczenie dla ochrony zdrowia publicznego.

Rezultaty projektu
Przełamanie barier technologicznych w diagnostyce i terapii arbowirusów i zwiększenie bezpieczeństwa zdrowotnego mieszkańców Pomorza i całego kraju. Projekt może wpynąć na skrócenie czasu diagnostyki, sprawne działania prewencyjne, oraz ograniczenie rozprzestrzeniania się wirusów i mniejszą liczbę hospitalizacji czy powikłań.

Projekt pt. „Innowacyjne metody diagnostyczne i terapeutyczne wobec zwiększonego zagrożenia arbowirusami spowodowanego zmianami klimatycznymi” jest zgodny z celami Regionalnej Agendy Badawczej „Wspólne Zdrowie Pomorza” i imiennie ujęty w Uchwale Zarządu Województwa Pomorskiego nr 1553/51/24.

Termin realizacji: 01.03.2026 r. - 31.05.2029 r.
Całkowity koszt projektu: 6 324 998,71 PLN
Wkład Funduszy Europejskich: 4 476 616,01 PLN
🔗 https://vaxican.com/projects/

Council of the European Union European Commission Fundusze Europejskie

11/05/2026

Strategy That Builds a Profitable Business 🎯
Meet Mateusz Sagan, MBA
Board Member, & at Vaxican

A strategic architect behind our organizational resilience and growth.
What makes great healthcare companies stand out? Strong governance, clear strategy, and leaders who ask the hard questions. That's Mateusz.

Co-founder, shareholder, and head of business development and finance at Vaxican, Mateusz brings over 25 years of experience managing international corporations, start-ups, and innovative deeptech projects. A seasoned executive, he has held CEO and Board positions in global organizations, with a strong track record in scaling technology companies.

For over 13 years, he has championed global biotech and medtech innovation, from capital raising and commercialisation to strategic management and venture building in . An Ambassador of the European Innovation Council (EIC) and co-creator and mentor of the acceleration programmes including MIT Enterprise Forum CEE and BioForum.

He is well known from:
- that identifies tomorrow's opportunities today
- Corporate governance expertise that protects stakeholders and mission
- Risk intelligence that keeps us competitive and compliant
- that drives sustainable growth

06/05/2026

From to 🔬➜💼
Łukasz Rąbalski, PhD is a CEO & Chief Science Officer of

A scientist who made Polish history.
When the world needed answers during the pandemic, Łukasz was in the lab. As the first Polish scientist to isolate and publish the genetic sequence of SARS-CoV-2 directly from a Polish patient, he demonstrated the kind of scientific excellence and determination that defines everything he does.
But here's what makes his leadership at Vaxican truly special: he doesn't just understand science. He understands how to transform it into impact in industry.

Łukasz has been conducting research on virus-like particles since 2012, developing their applications as veterinary vaccines, antigen presentation vectors for human therapies, and diagnostic tools.

He specialises in cutting-edge molecular biology and next-generation sequencing . His expertise earned him the role of consultant to the United Nations and the Military Institute of Hygiene and Epidemiology, and in 2023 he was awarded the individual MEiN Prize for scientific achievement.

His leadership philosophy:
🔹 Great science deserves great business ex*****on
🔹 Innovation thrives when scientists and entrepreneurs collaborate
🔹 must match excellence in the boardroom

As founder, majority shareholder, and the visionary behind Vaxican's proprietary eVLP platform, Łukasz leads with both rigour and vision.

30/04/2026

We achieved all three promised . And in one area, we went nearly 5× beyond the target.
Team hits all three milestones that unlocked the second tranche of our , bringing total secured capital to over 9 million PLN.

What did we actually achieve?

1. A real R&D center, built from scratch
We now operate a 230 m² semi-industrial lab equipped with ~3.5M PLN worth of specialized instruments. This gives us the infrastructure that, until recently, only large pharma companies could access.

2. A proprietary purification process: confirmed
We developed our own method to isolate particles, the tiny, engineered structures at the heart of our cancer vaccine platform. Getting our particles pure, stable, and ready for clinical use was crucial for further development.

3. Production yield, nearly 5× above target
For our lead cancer vaccine candidate (eVLP-HER2, targeting -positive breast cancer), we achieved production output far exceeding the minimum required level. Higher yield = lower cost. Lower cost = a cleaner path to clinical trials and future manufacturing at scale.

And on the top of that: We also signed a 6.3M PLN EU-funded agreement to develop next-generation diagnostics for arboviruses: mosquito- and tick-borne diseases like dengue and Zika, which are expanding rapidly into Europe due to climate change.

23/03/2026

We had the pleasure of presenting at the CANVAS Final Conference - Enhancing Cancer Vaccine Science for New Therapy Pathways, hosted by International Centre for Cancer Vaccine Science, University of Gdansk

Dr Łukasz Rąbalski, Founder & CEO of VAXICAN, delivered a talk on: "Development of an enveloped virus-like particle (eVLP) platform for therapeutic cancer immunovaccines: production scale-up and preclinical characterization of an HER2-targeting candidate"

The presentation covered Vaxican's progress in developing a modular, paramyxovirus-derived eVLP platform - designed as a scalable, off-the-shelf scaffold for therapeutic cancer vaccines targeting HER2-positive breast cancer. Preclinical work is carried out in consortium with Łukasiewicz - PORT, funded by the Medical Research Agency (Agencja Badań Medycznych) under the National Recovery Plan (KPO).

It was a valuable opportunity to connect with researchers working across cancer immunology, tumour biology and translational oncology - and to discuss how enveloped VLP technology fits into the evolving landscape of cancer immunotherapy.

. Fot. T.Nowicki.

27/02/2026

otrzymał rekomendację do pozyskania finansowania z Agencji Rozwoju Pomorza na projekt "Innowacyjne metody diagnostyczne i terapeutyczne wobec zwiększonego zagrożenia arbowirusami spowodowanego zmianami klimatycznymi"

Główny cel projektu:
Opracowanie i walidacja innowacyjnej, zintegrowanej platformy diagnostyczno-terapeutycznej w odpowiedzi na rosnące zagrożenie arbowirusami (w szczególności wirusami - DENV, Zachodniego Nilu - WNV i Kleszczowego Zapalenia Mózgu - TBEV), których rozprzestrzenianie jest potęgowane przez zmiany klimatycznymi.

Cel ten zostanie osiągnięty poprzez realizację dwóch komplementarnych zadań badawczo-rozwojowych:

1. Stworzenie szybkiej, bezpiecznej metody diagnostycznej opartej na sekwencjonowaniu nanoporowym (ONT), umożliwiającej kompleksową charakterystykę genomową arbowirusów.

Celem jest dostarczenie narzędzia (prototypu systemu) gwarantującego bezpieczeństwo pracy i dostarczającego bogatych danych genomowych w czasie poniżej 48 godzin, z potencjałem wdrożeniowym w różnych laboratoriach.

2. Zbadanie i rozwój innowacyjnej metody terapeutycznej wykorzystującej nanocząstki (np. złota) zdolne do penetracji błon komórkowych i potencjalnej dezaktywacji wirusów in vitro.

Celem jest opracowanie nowej strategii walki z infekcjami arbowirusowymi. Ostatecznym celem jest dostarczenie zaawansowanych, zwalidowanych rozwiązań znacząco zwiększających możliwości diagnostyczne (z naciskiem na szybką i pełną informację genomową), oraz weryfikujących potencjał nowego podejścia terapeutycznego w obliczu zagrożeń arbowirusowych.

Kwota dofinansowania: 4 476 616,01 zł

05/02/2026

🚀 Vaxican is growing, and so is our team!
As part of our consistent, long-term development strategy, we are expanding our team.
We are looking for motivated professionals to join us in Gdańsk:
If you are passionate about biotechnology and eager to work on innovative projects, join us!

🔗 Apply here:
👉 Biotechnology Specialist: https://www.pracuj.pl/praca/biotechnology-specialist-gdansk-kampinoska-25,oferta,1004621631
👉 Lab Assistant / Lab Technician: https://www.pracuj.pl/praca/lab-assistant-lab-technician-gdansk-kampinoska-25,oferta,1004621632

Adres

Ul. Kładki 24
Gdansk
80-822

Godziny Otwarcia

Poniedziałek	08:00 - 16:00
Wtorek	08:00 - 16:00
Środa	08:00 - 16:00
Czwartek	08:00 - 16:00
Piątek	08:00 - 16:00

Strona Internetowa

https://vaxican.com/

Ostrzeżenia

Bądź na bieżąco i daj nam wysłać e-mail, gdy Vaxican umieści wiadomości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu i możesz zrezygnować z subskrypcji w dowolnym momencie.

Chcesz aby twoja firma była na górze listy Firma Inżynieryjna w Gdansk?

Udostępnij

Kategoria

Firma z branży biotechnologii